Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
NCT ID: NCT05322850
Last Updated: 2025-12-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-08-16
Study Completion Date
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03802695
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Mixed Phenotype Acute Leukemia
+1 more
RECRUITING
PHASE1
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
NCT06551584
Acute Myeloid Leukemia
Acute Lymphoid Leukemia
Mixed Phenotype Acute Leukemia
+1 more
NOT_YET_RECRUITING
PHASE1
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
NCT05507827
Lymphoid Leukemia
ACTIVE_NOT_RECRUITING
PHASE1
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Mixed Phenotype Acute Leukemia
RECRUITING
PHASE2
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT04013685
Acute Myeloid Leukemia
Acute Lymphoid Leukemia
Myelodysplastic Syndromes
+3 more
ACTIVE_NOT_RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Myeloid Leukemia
Acute Lymphoid Leukemia
Mixed Phenotype Acute Leukemia
Acute Undifferentiated Leukemia
Chronic Myeloid Leukemia in Myeloid Blast Crisis
Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)
Chronic Myeloid Leukemia - Accelerated Phase
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orca-Q
Group Type
EXPERIMENTAL
Orca-Q
Intervention Type
BIOLOGICAL
All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orca-Q
All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \< 22 years of age at the time of diagnosis of malignancy
* Eligible for treatment at a pediatric HCT center
* Patients with the following histopathologically-confirmed diseases are eligible:
1. Acute myeloid, lymphoid, mixed phenotype or undifferentiated leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) as defined by:
* Marrow blasts \< 5% by morphologic examination
* Absolute neutrophil count \> 1.0 × 109/L
* Platelet count \> 100 × 109/L
* Absence of leukemic blasts in the peripheral blood by morphological examination, and
* No evidence of extramedullary disease
* CRi: All CR criteria except for residual neutropenia (\< 1.0 × 109/L) or thrombocytopenia (\< 100 × 109/L)
2. Myeloid or lymphoid blast crisis or accelerated phase developing in the setting of chronic myeloid leukemia is an allowed diagnosis provided that patients are in CR or CRi with regard to the blast crisis
* Planned to undergo myeloablative allogeneic hematopoetic cell transplant (MA-alloHCT) with a myeloablative conditioning regimen
* Available donor willing to donate PBSCs:
1. Related donor who is a 7 or 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
2. Matched unrelated donor who is a 7 or 8/8 match at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
3. Haploidentical related donor who is a ≥ 4/8 but \< 7/8 match at HLA-A, -B, -C, and -DRB1 (typed using DNA-based high-resolution methods), with at most one mismatch per locus
* Serum creatinine within normal range for age and estimated GFR by Schwartz equation \>70 ml/min/1.73m2. If serum creatinine is higher than normal, obtain creatinine clearance or nuclear medicine glomerular filtration rate. GFR of ≥ 70 mL/minute/1.73m2 is required.
* Cardiac ejection fraction at rest ≥ 50% by echocardiogram or radionuclide scan (MUGA)
* Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 70% or pulse ox on RA \>95% for patients who cannot cooperate with the PFTs
* Total bilirubin \< 1.5 times upper limit of normal (ULN) (\< 3 times if attributed to Gilbert's syndrome) and ALT/AST \< 4 times ULN
* Recipients in screening must screen negative for SARS-CoV-2 RNA using a PCR-based test prior to enrollment as follows:
1. The SARS-CoV-2 testing screening test should be timed such that the results are available prior to the start of the recipient's conditioning regimen. Efforts should be made to minimize the window of time between test result availability and the start of conditioning.
2. Recipients in screening who test positive for SARS-CoV-2 are ineligible but may be considered eligible for future trial participation provided that they are cleared for transplantation per the most current ASTCT guidelines (https://www.astct.org/connect/astct-response-to-covid-19).
* Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included).
* Written informed consent obtained from the subject and the subject or parental/legal representative permission and subject's assent, if applicable, stating that the subject agrees to comply with all the study-related procedures.
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for one year after transplantation to minimize the risk of pregnancy.
* Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g ., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for one year after transplantation.
* Age ≥ 18 and ≤ 50 years at time of enrollment
* Match to the patient as follows:
1. Matched related donor who is a 7 or 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high resolution methods
2. Matched unrelated donor who is a 7 or 8/8 match at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
3. Haploidentical related donor who is a ≥ 4/8 but \< 7/8 match at HLA-A, -B, -C, and -DRB1 (typed using DNA-based high-resolution methods), with at most one mismatch per locus
* Willing to donate PBSC for up to two consecutive days
* Able to donate within North America or Hawaii at a site that will employ a Spectra Optia Apheresis System for post-mobilization apheresis.
* Meets federal eligibility criteria for donors of viable, leukocyte-rich cells or tissues as defined by 21 CFR § 1271 2018 and all relevant FDA Guidance for Industry.
* Donors determined to be ineligible, based on the results of required testing and/or screening, may nonetheless be included if either apply, as per 21 CFR § 1271.65 2018:
1. The donor is a first-degree or second-degree blood relative of the recipient
2. Urgent medical need, meaning no comparable human cell product is available and the Recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the investigator.
* Meets any other criteria for donation as specified by standard NMDP guidelines (NMDP donors) or institutional/FACT standards (non-NMDP donors)
* Eligible for treatment at a pediatric HCT center
* Patients with the following histopathologically-confirmed diseases are eligible:
1. Acute myeloid, lymphoid, mixed phenotype or undifferentiated leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) as defined by:
* Marrow blasts \< 5% by morphologic examination
* Absolute neutrophil count \> 1.0 × 109/L
* Platelet count \> 100 × 109/L
* Absence of leukemic blasts in the peripheral blood by morphological examination, and
* No evidence of extramedullary disease
* CRi: All CR criteria except for residual neutropenia (\< 1.0 × 109/L) or thrombocytopenia (\< 100 × 109/L)
2. Myeloid or lymphoid blast crisis or accelerated phase developing in the setting of chronic myeloid leukemia is an allowed diagnosis provided that patients are in CR or CRi with regard to the blast crisis
* Planned to undergo myeloablative allogeneic hematopoetic cell transplant (MA-alloHCT) with a myeloablative conditioning regimen
* Available donor willing to donate PBSCs:
1. Related donor who is a 7 or 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
2. Matched unrelated donor who is a 7 or 8/8 match at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
3. Haploidentical related donor who is a ≥ 4/8 but \< 7/8 match at HLA-A, -B, -C, and -DRB1 (typed using DNA-based high-resolution methods), with at most one mismatch per locus
* Serum creatinine within normal range for age and estimated GFR by Schwartz equation \>70 ml/min/1.73m2. If serum creatinine is higher than normal, obtain creatinine clearance or nuclear medicine glomerular filtration rate. GFR of ≥ 70 mL/minute/1.73m2 is required.
* Cardiac ejection fraction at rest ≥ 50% by echocardiogram or radionuclide scan (MUGA)
* Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 70% or pulse ox on RA \>95% for patients who cannot cooperate with the PFTs
* Total bilirubin \< 1.5 times upper limit of normal (ULN) (\< 3 times if attributed to Gilbert's syndrome) and ALT/AST \< 4 times ULN
* Recipients in screening must screen negative for SARS-CoV-2 RNA using a PCR-based test prior to enrollment as follows:
1. The SARS-CoV-2 testing screening test should be timed such that the results are available prior to the start of the recipient's conditioning regimen. Efforts should be made to minimize the window of time between test result availability and the start of conditioning.
2. Recipients in screening who test positive for SARS-CoV-2 are ineligible but may be considered eligible for future trial participation provided that they are cleared for transplantation per the most current ASTCT guidelines (https://www.astct.org/connect/astct-response-to-covid-19).
* Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included).
* Written informed consent obtained from the subject and the subject or parental/legal representative permission and subject's assent, if applicable, stating that the subject agrees to comply with all the study-related procedures.
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for one year after transplantation to minimize the risk of pregnancy.
* Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g ., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for one year after transplantation.
* Age ≥ 18 and ≤ 50 years at time of enrollment
* Match to the patient as follows:
1. Matched related donor who is a 7 or 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high resolution methods
2. Matched unrelated donor who is a 7 or 8/8 match at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods
3. Haploidentical related donor who is a ≥ 4/8 but \< 7/8 match at HLA-A, -B, -C, and -DRB1 (typed using DNA-based high-resolution methods), with at most one mismatch per locus
* Willing to donate PBSC for up to two consecutive days
* Able to donate within North America or Hawaii at a site that will employ a Spectra Optia Apheresis System for post-mobilization apheresis.
* Meets federal eligibility criteria for donors of viable, leukocyte-rich cells or tissues as defined by 21 CFR § 1271 2018 and all relevant FDA Guidance for Industry.
* Donors determined to be ineligible, based on the results of required testing and/or screening, may nonetheless be included if either apply, as per 21 CFR § 1271.65 2018:
1. The donor is a first-degree or second-degree blood relative of the recipient
2. Urgent medical need, meaning no comparable human cell product is available and the Recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the investigator.
* Meets any other criteria for donation as specified by standard NMDP guidelines (NMDP donors) or institutional/FACT standards (non-NMDP donors)
Exclusion Criteria
* Prior myeloablative allogeneic HCT
* Currently receiving corticosteroids or other immunosuppressive therapy (topical corticosteroids or physiologic replacement hydrocortisone is allowed)
* Planned donor lymphocyte infusion (DLI)
* Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy) or alemtuzumab. Anti-thymocyte globulin is allowed only as specified in the protocol.
* Positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:
1. a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
2. the presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) \> 1000 by solid phase immunoassay
* Lansky play scale \< 70% or Karnofsky \<70%
* Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) \> 4
* Documented or suspected bridging fibrosis or liver cirrhosis
* Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment
* Seropositive for HIV-1 or -2, HTLV-1 or -2
* Known allergy or hypersensitivity to, or intolerance of, tacrolimus
* Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal or Streptomyces avidinii proteins
* Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
* Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected
* Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for one year following transplantation.
* Females who are known to be pregnant or breastfeeding and unwilling to cease breastfeeding.
* Any serious medical condition or abnormality in clinical laboratory tests that, in the Investigator's or Medical Monitor's judgment, precludes the Recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
* Administration of a vaccine containing live virus within 30 days prior to the first dose of trial treatment (conditioning regimen). Note: Most flu vaccines are killed viruses, with the exception of the intra-nasal vainer (Flu-Mist) which is an attenuated live virus and therefore prohibited for 30 days prior to first dose. Non-live versions of the COVID-19 vaccine are allowed.
* Prisoners or subjects who are involuntarily incarcerated, wards of state, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
* Evidence of active infection
* Seropositive for HIV -1 or -2, HTLV-1 or -2
* Positive for active or chronic Hepatitis B (HBV) based on serology \[HBV surface antigen (HBsAg), total anti-Hepatitis B core antibody (HBcAb, IgG and IgM), and Hepatitis B surface antibody (HBsAb)\] or by nucleic acid testing (NAT) testing. Donors with ambiguous HBV serology results should be tested for HBV by NAT.
* Positive for anti-Hepatitis C (HCV) antibody or HCV NAT
* Potential for Zika virus infection as defined as any of the following:
* Medical diagnosis of Zika virus infection in the past 6 months
* Residence in, or travel to, an area with active Zika virus transmission within the past 6 months.
* Sex within the past 6 months with a person who is known to have either of the risk factors listed above
* Donors determined to be ineligible based on the results of Zika virus screening may be determined to be eligible if:
i. The donor has no signs or symptoms consistent with active Zika virus infection and either of the following is true: ii. The donor is a first-degree or second-degree blood relative of the recipient iii. Urgent medical need, meaning no comparable human cell product is available and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the Investigator
* Aberrant CD45RA isoform expression by central laboratory testing
* Females who are pregnant or breastfeeding and unwilling to cease breastfeeding
* Currently receiving corticosteroids or other immunosuppressive therapy (topical corticosteroids or physiologic replacement hydrocortisone is allowed)
* Planned donor lymphocyte infusion (DLI)
* Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy) or alemtuzumab. Anti-thymocyte globulin is allowed only as specified in the protocol.
* Positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:
1. a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
2. the presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) \> 1000 by solid phase immunoassay
* Lansky play scale \< 70% or Karnofsky \<70%
* Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) \> 4
* Documented or suspected bridging fibrosis or liver cirrhosis
* Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment
* Seropositive for HIV-1 or -2, HTLV-1 or -2
* Known allergy or hypersensitivity to, or intolerance of, tacrolimus
* Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal or Streptomyces avidinii proteins
* Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
* Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected
* Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for one year following transplantation.
* Females who are known to be pregnant or breastfeeding and unwilling to cease breastfeeding.
* Any serious medical condition or abnormality in clinical laboratory tests that, in the Investigator's or Medical Monitor's judgment, precludes the Recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
* Administration of a vaccine containing live virus within 30 days prior to the first dose of trial treatment (conditioning regimen). Note: Most flu vaccines are killed viruses, with the exception of the intra-nasal vainer (Flu-Mist) which is an attenuated live virus and therefore prohibited for 30 days prior to first dose. Non-live versions of the COVID-19 vaccine are allowed.
* Prisoners or subjects who are involuntarily incarcerated, wards of state, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
* Evidence of active infection
* Seropositive for HIV -1 or -2, HTLV-1 or -2
* Positive for active or chronic Hepatitis B (HBV) based on serology \[HBV surface antigen (HBsAg), total anti-Hepatitis B core antibody (HBcAb, IgG and IgM), and Hepatitis B surface antibody (HBsAb)\] or by nucleic acid testing (NAT) testing. Donors with ambiguous HBV serology results should be tested for HBV by NAT.
* Positive for anti-Hepatitis C (HCV) antibody or HCV NAT
* Potential for Zika virus infection as defined as any of the following:
* Medical diagnosis of Zika virus infection in the past 6 months
* Residence in, or travel to, an area with active Zika virus transmission within the past 6 months.
* Sex within the past 6 months with a person who is known to have either of the risk factors listed above
* Donors determined to be ineligible based on the results of Zika virus screening may be determined to be eligible if:
i. The donor has no signs or symptoms consistent with active Zika virus infection and either of the following is true: ii. The donor is a first-degree or second-degree blood relative of the recipient iii. Urgent medical need, meaning no comparable human cell product is available and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the Investigator
* Aberrant CD45RA isoform expression by central laboratory testing
* Females who are pregnant or breastfeeding and unwilling to cease breastfeeding
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orca Biosystems, Inc.
INDUSTRY
Sponsor Role
collaborator
Florida Department of Health
OTHER_GOV
Sponsor Role
collaborator
University of Florida
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jordan Milner, MD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Site Status
RECRUITING
University of Miami
Miami, Florida, United States
Site Status
RECRUITING
Nicklaus Children's Hospital
Miami, Florida, United States
Site Status
RECRUITING
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCR41968
Identifier Type: OTHER
Identifier Source: secondary_id
UF-PED-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT05316701
ACTIVE_NOT_RECRUITING
PHASE3
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
NCT00412360
COMPLETED
PHASE3
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
NCT06865352
COMPLETED
PHASE1/PHASE2
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
NCT03849651
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
NCT01036009
COMPLETED
PHASE2
CD123 Redirected T Cells for AML in Pediatric Subjects
NCT04678336
TERMINATED
PHASE1
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
NCT00055653
COMPLETED
PHASE2
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
NCT01690520
COMPLETED
PHASE2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
NCT06839456
RECRUITING
PHASE1/PHASE2
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
NCT00795132
COMPLETED
PHASE2
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
NCT00004878
WITHDRAWN
PHASE2
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
NCT06381817
RECRUITING
PHASE3
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
NCT00025038
COMPLETED
PHASE2
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
NCT05350163
TERMINATED
PHASE1
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
NCT05088356
RECRUITING
PHASE1
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
NCT00450450
COMPLETED
PHASE3
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
NCT04836390
ENROLLING_BY_INVITATION
PHASE2
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879
TERMINATED
PHASE2
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
NCT02508038
RECRUITING
PHASE1
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
ACTIVE_NOT_RECRUITING
PHASE2
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
NCT00357565
COMPLETED
PHASE2
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
NCT00253513
COMPLETED
PHASE1/PHASE2
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
NCT01287104
COMPLETED
PHASE1
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT03842696
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01093586
COMPLETED
PHASE2